TEAM-DS - Children 6-17 with Down Syndrome
STUDY BASICS
Does your child have Down syndrome and attention deficit hyperactivity disorder (ADHD)? Your child may be eligible to participate in a research project to help learn how medications prescribed for children and adolescents with Down syndrome and ADHD influence behavior, learning and health. Compensation is provided.
STUDY PURPOSE
Children with Down Syndrome (DS) have a greater prevalence of ADHD than typically developing children. Despite this higher risk, we do not have a solid understanding of the relationship between DS and ADHD. Further, children with DS and ADHD are rarely treated with stimulant medication, even though this form of treatment is both effective and recommended for use in children with intellectual disability. Therefore, the purpose of this research study is to test the safety and effectiveness of stimulant treatment in children with DS+ADHD.
COULD THIS STUDY BE RIGHT FOR YOUR CHILD?
- Ages 6 to 17 years old
- Diagnosed with Down syndrome
- Overactivity, paying attention or distractibility are concerns
- Able to swallow liquid medicine
WHAT PARTICIPANTS CAN EXPECT
The study includes both telehealth visits and visits at Children’s Hospital of Pittsburgh. The study procedures will take place over 30 weeks:
- Initial Screen - child will complete cognitive and behavioral assessments. Parent/caregiver will complete parent reports.
- Medical Screen -
- Echocardiogram (ECHO): if record of prior normal ECHO is provided, this will not be performed
- Electrocardiogram (ECG)
- Collection of vital signs completed, such as height, weight, and blood pressure
- A medical examination
- Receive an in-home sleep study kit with detailed instructions for Obstructive Sleep Apnea (OSA) screening
- Study drug administration - Including varying doses of active study drug and placebo (inactive medication)
- Recurrent cognitive and behavioral assessments to determine efficacy
- Medical evaluations throughout to ensure safety
- Collaboration between parent, teacher and physician to determine optimal dosage
IRB: 2019-1016A
- Treatment Efficacy and safety of ADHD Medication in Down Syndrome (TEAM-DS)MEET THE RESEARCHER

Benjamin Handen
Benjamin Handen, Ph.D. is Professor of Psychiatry and Pediatrics at the University of Pittsburgh School of Medicine and Director of Research and Clinical Services at the Center for Autism and Developmental Disorders at Western Psychiatric Institute and Clinic. Dr. Handen is a clinical psychologist with over 40 years of experience in the field of autism and developmental disabilities. His research is focused upon the examination of psychopharmacology and psychosocial treatments in children and adults with developmental disabilities. He has a special interest in ADHD. In addition, Dr. Handen co-leads an international study on the course and development of Alzheimer’s Disease in adults with Down syndrome.